Actually I think today's trading is an over - reaction. However, you can certainly bet the company is hearing from its institutional holders. This makes me believe that what I had originally thought would be a fairly dull discussion at ASCO could be something more substantial. I have been a holder of this stock for several years. My thinking is that if I am getting frustrated with the lengthy and spotty testing programs on multiple drugs, those with hugely larger position must be bordering on anger. I'm starting to think that ASCO will provide some significant material on 214 or other pipeline progress. It could be wishful thinking and it's clearly speculation, but it sure would not surprise me at all. M.
I agree that the company would like to have the info for that presentation. I can think of no better stage. Hopefully, the CR material, the effectiveness and the lack of negative reactions will be quite compelling. Another PR reason for having the data ready by that period, is that the quarterly report and conference call is due around that time. MARK.
Our stock has been doing nicely over the past several weeks, even though it has yet to hit the 17's that we saw near year end. Perhaps one of the reasons for the progress is the expectations for a report on the early results on 214. We can expect both a conference call, on quarterly results, and an appearance at ASCO in early June. Here's hoping we have some spectacular news on "complete responses" to report. That would be an outstanding justification for those of us who have held the stock for a number of years. Good luck to the longs. MARK
Of course we don't know if the same positive scene is playing out with human patients. If it is,clearly the folks at MDA know it, as well as the patients. It is likely that Nektar also knows the positive news. I guess the question is could they keep a lid on this info, with all of these folks being aware of it. I don't know but we can surely hope so - both for the stricken that will now hve hope and the stockholders who have kept the faith. MARK
I was hoping that Nektar would use ASCO as the forum to announce top line results for the current 214 tests. However with an early June date for ASCO, that does not look likely. As the numbers are due in the second half of the year, the results will probably be several months away from that presentation. All we can hope for is an accelerated report or perhaps some comments relative to "complete response" successes. Here's hoping that we have something meaningful, positive and unique to put forward at the event. I am assuming that the company realizes that another recap of the pipeline would have very minor impact for such a significant audience. MARK
We may also get a better understanding as to why the super bowl ad was placed, and if that strategy was successful. An update on the 214 tests would be useful and, of course, any indication of complete response results. I would be most interested to hear an update regarding 102. Just ignoring the product after the major dollars that have been spent would not be helpful. And, I would sure like to know what is happening on Cipro. Some suggested timetable would be educational.. As a matter of fact, a timeline for all of our phase 3 products would be very useful MARK i
is for HR and the rest of the management team to stop selling stock and show a little confidence in the company that is not only paying them very well, but also providing a ridiculous number of options. It would be one thing if the shareholders were profiting handsomely from the company but at this point, and for a number of years, we have not. Even the institutions have to be wondering about this trend. Officers should show their belief by being buyers. I understand the concept of diversification, but this selling is truly not helpful. Many shareholders have been incredibly loyal to Nectar, it's time for management to return the favor. M.
As I indicated in an earlier post, the volume makes it clear that institutions have been on both sides of numerous recent trades. It is not only important to see who new buyers are, but to be sure old holders are still with us. The most significant positive sign would be if some major holders took advantage of the price break to add to their holdings. These folks know us the best, and renewed buying would be a welcome sign of confidence. MARK
With this kind of volume it is clear that institution are both buying and selling. Therefore, it will be interesting to note who has been doing the buying and conversely the selling. Hopefully, our largest holders, those who know us best, have taken this opportunity to add to their positions. We will see. Patience may be a virtue, but eventually institutions must see the clouds part and a bit of sunshine begin to come through. This next conference call is vital and must give more then vague promises. A firm timeline on all phase three products would be helpful, as would any word on 214 complete responses. Also, the company view on Movantik sales and pain drug progress would be helpful. MARK